Postdoctoral Opportunities in Tumor Microenvironment/Immunology
Are you looking for postdoctoral opportunities? We may be looking for you! OHSU, home of the Knight Cancer Network, is located in beautiful Portland, Oregon. Contact our labs below to find out more.
Julia Maxson, Ph.D.: We study how genomic changes manifest at the cellular level to promote cancer formation and progression. We focus on understanding how genetic alterations cooperate to drive leukemia to develop therapeutic strategies.
Lara E. Davis, M.D.: We focus on translational sarcoma research. Current projects include targeting the osteosarcoma immune microenvironment through analysis of tumor biopsies and in vivo modelling; identification and characterization of unrecognized kinase fusions in complex karyotype sarcomas; and optimizing CDK4 inhibition as a method to increase sarcoma sensitivity to chemotherapy. All projects incorporate human tumor specimens and we frequently conduct correlative.
Gordon Mills, M.D., Ph.D.: Join a highly productive dynamic translational research effort, characterizing mechanisms of drug sensitivity and resistance in human tumors. Access to human tissues as well as a broad array of wet bench and bioinformatics tools provides a rich environment for fellows to explore. Mills Lab
Sud Anand, Ph.D.: We are broadly interested in identifying and characterizing non-coding RNAs in the host cells that impact tumor progression. We welcome candidates that can lead efforts to understand functions of non-coding RNAs in immune cells in the tumor microenvironment.
Amy Moran, Ph.D.: Work in a translational cancer immunotherapy lab evaluating the cross talk between sex steroids and immune cell function. Current projects include the role of the microbiome in modulating immuno-therapy responses and immune cell function (in a clinical trial and mouse model) and novel mechanisms of action of non-conventional inhibitors of T & NK cell function.
Jonathan Brody, Ph.D.: We focus on many molecular aspects of pancreatic cancer, including developing ways to target a novel pro-survival network in pancreatic cancer cells and optimizing current targeted therapies used in the clinic (i.e., an interest in personalizing therapy for pancreatic cancer patients, PanCAN, RAN grant PI).
Robert Eil, M.D., Ph.D.: We focus on identifying and over-coming novel mechanisms of tumor-induced immune evasion, with the goal of engineering novel immune therapies and improving existing ones.
Ferdinando Pucci, Ph.D.: We focus on understanding humoral immune responses to malignant transformation and how they affect cell-mediated immunity, with the goal of developing next generation cancer vaccines. We couple genetic engineering and in vivo imaging of sentinel lymph nodes to study antigen-specific immune reactions to tumor-derived extracellular vesicles.
Rosalie Sears, Ph.D.: Work on pancreatic cancer focused on tumor heterogeneity, lineage plasticity, epigenetic regulation and mechanisms of therapeutic resistance. We use sophisticated omic and image analysis of patient tumors, patient-derived models using 3D bioprinting and genetic mouse models. Candidates must have a Ph.D. and/or M.D. degree and extensive training in the areas of cancer biology, molecular biology, biochemistry, cell biology, and mouse modeling.
Lisa M Coussens, Ph.D.: We are broadly interested in understanding signals controlling innate and adaptive leukocyte responses and activities in solid tumors. Multiple projects are available to examine myeloid - T cell cross talk and mechanisms regulated by complement proteins as mediators of tumor progression and anti-tumor immunity using both mouse models of human cancer and clinical specimens.
Josh Walker, M.D., Ph.D.: Our research focuses on understanding the intrinsic and microenvironmental factors that regulate T cell effector dysfunction in cancer, extending from the differential effects of antigen presentation and priming on T cell effector fate to the effects of novel combinations of chemotherapy, radiotherapy, and immunotherapy on T cell effector function in advanced cancer. Our work utilizes both preclinical models with defined tumor antigens where the timing and strength of T cell stimulation can be manipulated as well as a range of clinical samples in order to explore this biology.
Sanjay Malhotra, Ph.D.: We are interested in design and discovery of small-molecule probes to explore biology and medicine. Our translational research leverages multi-disciplinary approach in chemistry, biology, pharmacology, molecular modeling, in vitro and patient-derived models to use these molecules to probe complex biological processes and to pursue new therapeutic opportunities in cancer and other diseases.
Megan Ruhland, Ph.D.: We are broadly interested in understanding the who, what, when and where of antigen presentation in the lymph node. In particular we focus on the pathways used by myeloid cell populations to bring tumor-derived antigen into the lymph node and subsequently seed antigen into lymph node resident cell populations